Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$111.62-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · CORT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $112, CORT's earnings are too small for P/E to mean much; on sales it trades at 16× p/s (5.5× the 2.9× p/s peer median, and 1.3× even its own history). At a normal multiple the price implies ~47% near-term growth vs our ~63% forecast. That gap is an optionality premium a financial-multiple model can't price — our $76 fair value covers only the as-is business, low confidence. Analysts target $50–$165. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $135.00 | — | — | Analyst | low |
| Peer P/FCF | 12M | $12.76 | 14.1 | 0.90 | TTM | low |
| Peer P/S | 12M | $20.39 | 2.9 | 7.02 | TTM | low |
| Peer P/E | 3Y | $88.05 | 16.1 | 5.48 | Hist. CAGR(prov.) | medium |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$50.00 – $165.00 (median $135.00) · 7 analysts · as of 2026-08-18
Flags: expensive valuation, weak execution quality. Capped at elevated by the Mania regime.
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 404% over what the business is worth with no growth; closing that gap needs roughly 3.8 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.46/sh owner earnings.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| Peer P/S | 3Y | $49.75 | 2.9 | 17.12 | guidance | medium |
| Peer P/E | 5Y | $116.44 | 16.1 | 7.25 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $65.80 | 2.9 | 22.65 | guidance | medium |